Callan JMB Inc. provides integrative logistics services for healthcare organizations and emergency management agencies, including fulfillment, storage, monitoring, cold-chain logistics and specialized distribution. Company updates commonly address emergency preparedness contracts, reverse distribution of vaccines and pharmaceuticals, regulated product handling, government relationships and business updates tied to healthcare supply-chain resilience.
Recurring developments also include the Atlas Complex in Marion, Alabama, a medical, pharmaceutical and logistics campus supporting QA/QC, cold-chain logistics, warehousing and domestic distribution. Other updates cover pharmaceutical onshoring initiatives, independent manufacturing oversight, quality-control governance, collaboration activity with life-sciences partners, financial results, investor communications and legal or listing-related corporate matters.
Callan JMB (NASDAQ: CJMB) announced ground-breaking at the Atlas Complex in Marion, Alabama, marking completion of a strategic partnership with Alabama State University to develop an integrated pharmaceutical manufacturing ecosystem aimed at strengthening U.S. domestic production, supply chain resilience, and national medical preparedness.
The partnership includes the launch of the Marion 9 Biomanufacturing Center, where Callan JMB will provide logistics, compliance, warehousing, facility leasing, and supply chain management infrastructure. According to Callan JMB, the project is forecast to generate an estimated $500 million in annual gross revenues, with the company entitled to a 21% participation, implying approximately $105 million in first-year revenue and over $400 million over a five-year agreement.
The Atlas Complex is intended as a shared healthcare and life sciences campus supporting academic, industry, healthcare, and government collaborators, with forecasts of more than 150 direct high-skilled jobs and about 300 indirect jobs across Alabama.
Callan JMB (NASDAQ: CJMB) announced a strategic partnership with Alabama State University to develop an integrated U.S. pharmaceutical manufacturing ecosystem aimed at enhancing domestic production, supply chain resilience, workforce development, and national medical preparedness.
Under the agreement, Callan JMB would provide operational infrastructure, including logistics, regulatory compliance, warehousing, facility leasing, supply chain management, housing support, and related services. Callan JMB would receive 21% of gross revenue from qualifying pharmaceutical manufacturing operations. Management believes the initiative could represent a potential $414 million five-year revenue opportunity and, under current assumptions, could ultimately support annual gross revenues approaching $500 million, implying about $105 million in annual revenue to Callan JMB, subject to successful execution. An official partnership announcement is scheduled for July 16, 2026, with university, industry, government, and community leaders.
Callan JMB (NASDAQ:CJMB) announced a strategic partnership with Alabama State University to support workforce development, applied research, and industry collaboration at the planned Atlas Complex pharmaceutical and medical logistics campus in Marion, Alabama.
Atlas is designed to support a manufacturing ecosystem capable of generating over $430 million in annual revenue at maturity while creating high-quality jobs and strengthening U.S. pharmaceutical supply chains.
Callan JMB (NASDAQ:CJMB) received a State of Oregon Vaccines for Children (VFC) Program PIN authorization, enhancing its role in pediatric public health logistics.
The approval expands the company’s ability to store, manage, prepare, and distribute pediatric vaccines and other temperature-sensitive medical materials for routine operations and targeted response efforts.
Callan JMB (NASDAQ:CJMB) expanded and extended a long-standing public sector infrastructure engagement worth about $175,000 per month for the next six months, or $1.05 million in projected recurring revenue. The amended agreement continues operational support through the second half of 2026 under an active government initiative.
Callan JMB (NASDAQ: CJMB) announced the Atlas Complex, a planned 150-acre multi-use pharmaceutical, logistics and life-sciences campus in Marion, Alabama, launched April 20, 2026.
The project includes a partnership with Walker’s Pharmaceuticals of India, adaptive reuse of historic infrastructure, pursuit of a Foreign-Trade Zone subzone, and expectations to create approximately 250–300 jobs while supporting onshoring, QA/QC, cold-chain logistics, and domestic distribution.
Summary not available.
Callan JMB (NASDAQ:CJMB) executed rapid reverse distribution of critical vaccines and pharmaceuticals to multiple jurisdictions on April 7, 2026 under a longstanding Public Health Emergency Preparedness contract. The company coordinated receipt, inspection, cold-chain storage and thermal-shipping deployment to redirect short-dated inventory to areas experiencing localized outbreaks.
This redistribution aims to preserve product integrity, avoid waste, and support fiscal stewardship of federal funds by moving usable stock from holding jurisdictions to points of dispensing per public health leadership direction.
Callan JMB (NASDAQ: CJMB) reported full‑year 2025 results and provided a business update on March 31, 2026. Revenue was $5.7M versus $6.6M in 2024; gross profit $2.1M and loss from operations $7.0M. Cash and cash equivalents were $2.1M.
The company highlighted new commercial agreements including a manufacturing oversight deal with Attune, a joint venture with Revival Health, expansion into India, renewed government contracts (Chicago and Oregon), vaccine lease programs, and an upgraded Sentry Monitoring System.
Callan JMB (NASDAQ: CJMB) announced independent infrastructure and oversight support for U.S. scale-up of the JKB-122 (Lodonal™) immune restoration platform on March 27, 2026.
Callan JMB will validate manufacturing, quality systems, and supply chain readiness to support Phase 2b/3 clinical advancement, U.S. GMP scale-up, and alignment with BARDA, DoD, and VA federal standards.